236 Studies Now Enrolling
Menu
Search
Medical Condition
- Show all (236)
- Addiction (3)
- Allergy, Asthma, & Immunology (1)
- Autoimmune Disorders (3)
- Bone & Muscle (2)
- Cancer (10)
- COVID-19 (Coronavirus) (8)
- Diabetes (7)
- Ear, Nose and Throat (7)
- Endocrine & Metabolic Disease (2)
- Gastrointestinal and Digestive Diseases (3)
- Hair and Skin Disorders (1)
- Healthy Volunteers (45)
- Heart Disease (18)
- Infectious Disease (11)
- Insomnia (1)
- Liver Disease (17)
- Lung Disease (2)
- Neurological Disorders (30)
- Nutrition (2)
- Obesity (8)
- Obstetrics & Gynecology (10)
- Pediatrics (15)
- Psychiatric Disorders (9)
- Rehabilitation (2)
- Stroke (2)
- Transplant (16)
- Vascular Conditions (1)
Displaying 1 - 7 of 7
Condition: Transplant / Kidney Transplant
Investigator: Lloyd Ratner, MD, MPH, FACS
Status: Currently Recruiting
This study is testing whether giving an investigational drug called C1 esterase inhibitor (C1INH) directly into the donor kidney before transplant can improve kidney function one year after surgery. At the time of the deceased donor kidney transplant, participants will be randomly assigned to received a kidney that has been treated with either C1INH or a…
Condition: Transplant / Kidney Transplant
Investigator: Joshua Weiner, MD
Status: Currently Recruiting
The goal of this clinical trial is to learn if an investigational medication called siplizumab can prevent rejection of a kidney transplant patients with end stage kidney disease. The study will compare two different doses of siplizumab to a medication that is standardly used post kidney transplant to prevent rejection, rabbit anti-thymocyte globulin (rATG…
Condition: Cancer / Leukemia
Investigator: Nobuko Hijiya, MD
Status: Currently Recruiting
This is a phase 1 study for participants with relapsed/refractory acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or juvenile myelomonocytic leukemia (JMML) diagnosis. This study will observe the safety, side effects, and best dose of Imetelstat as an investigational drug, or drug that is not approved by the Food and Drug Administration (FDA…
Condition: Transplant / Kidney Transplant
Investigator: Lloyd Ratner, MD, MPH, FACS
Status: Currently Recruiting
This study is testing whether a new investigational medicine called frexalimab can safely and effectively prevent kidney transplant rejection compared to tacrolimus, a standard medication currently used after transplant. Participants will be randomly assigned to receive either frexalimab (given by injection every 4 weeks) or tacrolimus (taken as capsules…
Condition: Transplant / Kidney Transplant
Investigator: Lloyd Ratner, MD, MPH, FACS
Status: Currently Recruiting
The main goal of this clinical trial is to determine if an investigational medication called VEL101 is safe, well tolerated, and effective in people receiving a new kidney transplant. Participants will be randomly assigned to 2 different doses of VEL-101 or to tacrolimus, which is standardly used post-transplant to prevent rejection. Participants will be…
Condition: Cancer / Leukemia
Investigator: Nobuko Hijiya, MD
Status: Currently Recruiting
This study will enroll with children, adolescents and young adults that are less than 22 years old that have returned or 'relapsed' acute myeloid leukemia (AML) diagnoses. Within this group, the study is also targeting those are also unable to receive additional chemotherapy treatments containing anthracycline, which is a type of antibiotic that…
Condition: Cancer / Leukemia
Investigator: Nobuko Hijiya, MD
Status: Currently Recruiting
This study is called a screening study and the purpose of this study to find better ways to diagnose and treat leukemia that has come back after treatment or difficult to treat. Bone marrow, blood, and medical information about cancer and treatment will be collected. The results from this screening study may give other information about leukemia that is…